Abstract
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) with a strong genetic component [1,2]. Genome-wide association studies (GWAS) have successfully identified over 240 genetic loci that are statistically associated with risk of developing IBD, and these associations provide valuable insights into disease pathobiology. Building on GWAS findings, conventional polygenic risk scores (cPRS) aim to quantify the aggregated disease risk based on DNA variation, and these scores can identify individuals at high risk. While stratifying individuals based on cPRS has the potential to inform clinical care, the development of novel therapeutics requires deep insight into how aggregated genetic risk leads to disruption of specific biological pathways. Here, we developed a pathway-specific PRS (pPRS) methodology to assess IBD common variant genetic risk burden across 31 manually curated pathways. We first prioritized 206 genes based on comprehensive fine-mapping and eQTL colocalization analyses of genome-wide significant IBD GWAS loci and 58 highly penetrant genes based on their involvement in early onset IBD or autoimmunity-related colitis. These 264 genes were assigned to at least one of the 31 pathways based on Gene Ontology annotations and manual curation. Finally, we integrated these inputs into a novel pPRS model and performed an extensive investigation of IBD disease risk, severity, complications, and anti-TNF treatment response by applying our pPRS approach to three complementary datasets encompassing IBD cases and controls. Our analysis identified multiple promising pathways that can inform drug target discovery and provides a patient stratification method that offers insights into the biology of treatment response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by AbbVie.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from UK Biobank (https://www.ukbiobank.ac.uk/), the PANTS study (https://www.ibdresearch.co.uk/pants/), and the RISK consortium (https://www.crohnscolitisfoundation.org/research/current-research-initiatives/pediatric-risk-stratification). UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC), which covers the UK. In Scotland, UK Biobank has approval from the Community Health Index Advisory Group (CHIAG). The RISK study is part of the Crohn's and Colitis Foundation and covered by the Crohn's and Colitis Foundation Ethics Committee (https://www.crohnscolitisfoundation.org/about/transparency). The PANTS protocol and related documents have been reviewed by the Sponsor (Mr Chris Gardner on behalf of Royal Devon and Exeter NHS Foundation Trust, Exeter, UK) and the South West - Exeter Research Ethics Committee (REC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures CAB, MM, WZ, JK, EAK, JFD, MCL are employees of AbbVie. YL, JWD, SC were employees of AbbVie at the time of the study. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
Data Availability
All data produced in the present work are contained in the manuscript.
